The following are references not included in the above summary should you wish to take a deeper look into the data:
Outcomes in Patients with PSO and/or PsA who Develop COVID-19 Illness
-
- Vispi M, Corradin T, Peccianti C, et al. Psoriasis, biological drugs and coronavirus disease 2019: real life experience of two Italian provinces. Dermatol Rep. 2020;12(1):8642. doi:10.4081/dr.2020.8642
- Zen M, Fuzzi E, Astorri D, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. doi:10.1016/j.jaut.2020.102502
- Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases — case series from New York. N Engl J Med. 2020;383(1):85-88. doi:10.1056/NEJMc2009567.
- Allocca M, Guidelli GM, Borroni RG, et al. Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan. Pharmacol Res. 2020;160:105061. doi:10.1016/j.phrs.2020.105061
- Kutlu Ö, Metin A. Dermatological diseases presented before COVID-19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther. 2020;33(4):e13509. doi:10.1111/dth.13509
- Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
- Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S. Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)? J Dermatolog Treat. Published June 30, 2020. doi:10.1080/09546634.2020.1782819
Effect of Systemic Treatments on COVID-19 Illness
- Pirro F, Caldarola G, Chiricozzi A, et al. The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. J Dermatolog Treat. Published August 4, 2020. doi:10.1080/09546634.2020.1800578
- Georgakopoulos JR, Mufti A, Vender R, Yeung J. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2020;83(4):1212-1214. doi:10.1016/j.jaad.2020.07.021.
- Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM. The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(5):1523-1526. doi:10.1016/j.jaad.2020.06.1014.
- Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(2):677-679. doi:10.1016/j.jaad.2020.05.035
- Fougerousse AC, Perrussel M, Bécherel PA. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. J Eur Acad Dermatol Venereol. Published online June 21, 2020. doi:10.1111/jdv.16761.
- Wang CJ, Truong AK. COVID-19 infection on IL-23 inhibition. Dermatol Ther. Published online July 14, 2020. doi:10.1111/dth.13893
- Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. Dermatol Ther. 2020;33(6):e13961. doi:10.1111/dth.13961
- Olisova OY, Anpilogova EM, Svistunova DA. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient. Dermatol Ther. 2020;33(4):e13668. doi:10.1111/dth.13668
- Valenti M, Facheris P, Pavia G, et al. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab. Dermatol Ther. 2020;33(4):e13708. doi:10.1111/dth.13708
- Benhadou F, Del Marmol V. Improvement of SARS-CoV-2 symptoms following guselkumab injection in a psoriatic patient. J Eur Acad Dermatol Venereol. 2020;34(8):e363-e364. doi:10.1111/jdv.16590
- Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158
- Facheris P, Valenti M, Pavia G, et al. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab. Int J Dermatol. 2020;59(8):e267-e268. doi:10.1111/ijd.15008
- Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(6):e254-e255. doi:10.1111/jdv.16468
